MacroGenics Announces Clinical Results From Cohort A Part 1 Of Phase 2/3 MAHOGANY Study Of Margetuximab In Combination With Retifanlimab In Gastroesophageal Adenocarcinoma At ESMO 2021
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A78% of patients had tumor shrinkage…